incremental shuttle walking test predicts survival in non
play

Incremental shuttle walking test predicts survival in non-group 1 - PowerPoint PPT Presentation

Incremental shuttle walking test predicts survival in non-group 1 pulmonary hypertension without a ceiling effect C. Billings 1 , R. Lewis 1 , J. Hurdman 1 , I. Armstrong 1 , I. Smith 1 , M. Austin 1 , C. Elliot 1 , A. Charalampopoulos 1 , I.


  1. Incremental shuttle walking test predicts survival in non-group 1 pulmonary hypertension without a ceiling effect C. Billings 1 , R. Lewis 1 , J. Hurdman 1 , I. Armstrong 1 , I. Smith 1 , M. Austin 1 , C. Elliot 1 , A. Charalampopoulos 1 , I. Sabroe 1 , A. Lawrie 2 , R. Thompson 2 , R. Condliffe 1 , D. Kiely 1 1 Sheffield Pulmonary Vascular Disease Unit, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital - Sheffield (United Kingdom), 2 Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Medical School - Sheffield (United Kingdom) Background • 6-MWT is a widely used sub-maximal walking test in pulmonary hypertension • ISWT externally paced incremental exercise test 1 • Previously shown that ISWT distance predicts survival in Group 1 PAH 2 Methods • Data from ASPIRE registry • ISWT within 3/12 of RHC • Treatment naïve and have non-group 1 pulmonary hypertension 1. Singh S et al, Thorax 2008 2. Billings CG et al, J Heart and Lung Transplant 2017

  2. Incremental shuttle walking test predicts survival in non-group 1 pulmonary hypertension without a ceiling effect Results n 1 year mortality % Band 5 Band 4 ISWD (m) 0-120 248 20.2 Band 3 130-420 203 9.4 Band 2 >420 28 0 Band 1 ISWD (%pred) 0-20 248 21.1 Band 1 ISWD m: 0-30; Band 2: 40-120; Band 3: 130-250; >20-60 212 8.0 Band 4: 260-420; Band 5: 430 - 1020 >60 21 0 Billings CG, Lewis R et al,

  3. Incremental shuttle walking test predicts survival in non-group 1 pulmonary hypertension without a ceiling effect Conclusion • ISWD and ISWD%pred correlates with symptoms and haemodynamics • ISWD predicts survival in non-group 1 PH • Can be used to risk stratify patients • Provides an alternative field walking test to 6MWT Robert Lewis was fully funded to attend the ERS by Pulmonary Vascular Research Institute

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend